SeaStar Medical (ICU) to Release Quarterly Earnings on Wednesday

SeaStar Medical (NASDAQ:ICU) is expected to be issuing its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.97) per share and revenue of $0.4860 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

SeaStar Medical (NASDAQ:ICU) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). The company had revenue of $0.49 million for the quarter, compared to analysts’ expectations of $0.44 million. SeaStar Medical had a negative net margin of 828.62% and a negative return on equity of 146.29%. On average, analysts expect SeaStar Medical to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

SeaStar Medical Stock Performance

Shares of NASDAQ:ICU opened at $3.19 on Wednesday. The stock has a 50 day moving average of $3.68 and a 200 day moving average of $3.37. The company has a market cap of $12.76 million, a PE ratio of -0.66 and a beta of -1.05. SeaStar Medical has a 12-month low of $2.07 and a 12-month high of $12.50.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ICU. Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a report on Friday, July 17th. Wall Street Zen lowered SeaStar Medical from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Maxim Group set a $8.00 price target on SeaStar Medical and gave the stock a “buy” rating in a research report on Thursday, May 14th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, SeaStar Medical currently has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Investors Weigh In On SeaStar Medical

Several hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd boosted its holdings in SeaStar Medical by 395.4% during the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after acquiring an additional 48,674 shares during the period. Jane Street Group LLC purchased a new stake in SeaStar Medical in the fourth quarter worth $30,000. Finally, Millennium Management LLC purchased a new stake in SeaStar Medical in the third quarter worth $102,000. 1.69% of the stock is currently owned by hedge funds and other institutional investors.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.